From Nasdaq: 2025-06-10 16:35:00

Recursion Pharmaceuticals (NASDAQ: RXRX) is cutting costs and restructuring to extend its financial runway. Investors reacted positively, with the stock closing 1.6% higher than the S&P 500’s 0.55% increase. The company plans to reduce its workforce by 20%, incurring $11 million in charges this year. Cash burn is expected to decrease, with over $500 million in cash reserves by the end of the quarter. Despite job cuts, Recursion’s cash runway is projected to last until the fourth quarter of 2027, indicating a strategic move towards sustainability. This move has left investors cautiously optimistic about the company’s future.



Read more at Nasdaq: Why Recursion Pharmaceuticals Was Bouncing Higher on Tuesday